Content area

|
|

Hyperterm intraperitoneal kemoterapi ved den primære operation for gastrointestinal cancer

Forfatter(e)
Thea Helene Degett1, Hans-Christian Pommergaard2 & Ismail Gögenur1 1) Center for Surgical Science, Sjællands Universitetshospital, Køge 2) Gastroenheden, Kirurgisk Sektion, Hvidovre Hospital Ugeskr Læger 2017;179:V06160454
Reference: 
Ugeskr Læger 2017;179:V06160454
Blad nummer: 
Sidetal: 
2-5
Hyperthermic intraperitoneal chemotherapy at the primary gastrointestinal cancer operation
Up to 20% of the patients who undergo radical surgery for colorectal cancer experience recurrence. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have shown to be effective treatment of peritoneal carcinomatosis. HIPEC administered at the primary operation in high-risk patients may also be effective in preventing peritoneal carcinomatosis and improve survival in patients with advanced gastrointestinal cancer.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Annette Randløv | 25/05
4 kommentarer
af Andreas Gothardt Lundh | 21/05
1 Kommentar
af Søren Dalsgaard | 20/05
1 Kommentar
af Anette Bygum | 19/05
10 kommentarer
af Hans-Iver G. F.-D Kley | 18/05
1 Kommentar
af Per Bonding | 17/05
1 Kommentar